Patents by Inventor Pierre Caudrelier

Pierre Caudrelier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040058861
    Abstract: The present invention provides a method for controlling viral rebound in HIV+ individuals after termination of anti-retroviral therapy, the method comprising administering to an HIV+ individual who has undergone anti-retroviral therapy that has been terminated and which HIV+ individual has a viral load of less than or equal to 10,000 copies per ml of plasma and a CD4+ level greater than or equal to 300 cells per mm3, at least one lipopeptide comprising a peptide chain of 7 to 100 amino acids which comprises at least one CTL epitope of an HIV protein and which is linked by covalent attachment, optionally via a linker moiety, to a lipid chain comprising from 8 to 20 carbon atoms.
    Type: Application
    Filed: September 7, 2001
    Publication date: March 25, 2004
    Inventors: Pierre Caudrelier, Raphaelle El Habib, Michel Klein
  • Patent number: 6214342
    Abstract: Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal antibody directed against the human LFA-1 molecule in the two hours after grafting and then administering daily dosing during a period of approximately nine days.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: April 10, 2001
    Assignee: Imtix-Sangstat
    Inventors: Gilles Alberici, Pierre Caudrelier, Brigitte Le Mauff, Maryvonne Hourmant, Jean-Paul Soulillou